Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 湖南景峰医药股份有限公司主营业务医药产品的研发、制造与销售。 公司专注医药健康产业，涉足药品研发、生产、销售等领域，产品涵盖了心脑血管、抗肿瘤、骨科、妇儿等用药领域。目前公司拥有大容量注射剂、小容量注射剂（含抗肿瘤类）、冻干粉针剂（含抗肿瘤类）、注射乳剂、硬胶囊剂、丸剂、颗粒剂、气雾剂、酊剂、口服乳、中药饮片以及原料药等通过国家GMP认证的生产线二十余条。除此之外，有数条原料药生产线通过了中国NMPA认证。 多年来，公司坚持“走与国际接轨的仿制药产业化道路”战略，实施以高壁垒仿制药为主、长短结合、多维研发生产管线并进的战略布局。
Main Business 医药产品的研发、制造与销售。
Legal Representative 杨栋
Top Executives
董事长(代)：张莉
董事：马学红,杨栋,叶高静,张莉,谢树青
独立董事：刘亭,钟少先,徐一民
Top 5 Shareholder
Shareholder name Nature Holding Date
叶湘武限售股13.86%30/09/2024
中国长城资产管理股份有限公司流通A股12.92%30/09/2024
平江县国有资产管理局流通A股1.26%30/09/2024
高盛公司有限责任公司流通A股0.84%30/09/2024
陆琦流通A股0.67%30/09/2024
Company Secretary 张莉
Solicitors 北京市中伦律师事务所
Auditors 立信会计师事务所（特殊普通合伙）
Tel No 0736-7320908
Fax No 0736-7320908
Website www.jfyiyao.com
Email ir@jfzhiyao.com
Company Address
Register: 湖南省常德经济技术开发区樟木桥街道双岗社区桃林路661号（双创大厦17楼）
Office: 湖南省常德经济技术开发区檀木桥街道双岗社区桃林路661号（双创大厦）
Listing Date 03/02/1999
Shares Capital
Shares Capital: 879,774,351
Total A Share: 879,774,351
Listed A Share: 788,900,387
Non-tradable A Share: 90,873,964
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.245
DPS(RMB)* --
NBV Per Share(RMB)* ¥ -0.056
Market Capitalization(RMB) 3.432B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.